Jodi Lavin-Tompkins, director of Accreditation and Content Development at the Association of Diabetes Care & Education Specialists (ADCES) highlights the key themes of the society’s annual meeting this year, and what the diabetes community can look forward to at the educational sessions.
- How do you feel about the 2022 ADCES Annual Conference being an in-person event as opposed to the virtual congresses of recent years? (00:15-01:26)
- What will be the key learning themes of this year’s event? (01:26-02:07)
- What can we look forward to in the educational sessions? (02:07-04:02)
- What are the greatest challenges currently facing the diabetes community? (04:02-04:46)
- Why should healthcare professionals attend the 2022 ADCES Annual Conference? (04:46-05:46)
Disclosure: Jodi Lavin-Tompkins has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Share this Video
Related Videos In Diabetes
John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He […]
Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and was FDA approved in November 2022; Orforglipron, an oral, non-peptide glucagon-like […]
Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven Nissen (Heart, Vascular and Thoracic Institute, Cleveland Clinic Center for Clinical Research, Cleveland, OH, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!